Follicular Lymphoma

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma (10-18-2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma (01-5-2017)

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan® (rituximab) plus chemotherapy, and should now be... Continue Reading

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma (12-15-2016)

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (08-16-2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (06-20-2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma (06-8-2016)

Genentech, announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL). The study compared Gazyva® (obinutuzumab)... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (12-17-2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients (05-28-2014)

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (09-4-2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma (02-8-2013)

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of... Continue Reading

Next Page »